Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Treatment of pancreatic cancer with intravenous vitamin C: a case report.

Drisko JA, Serrano OK, Spruce LR, Chen Q, Levine M.

Anticancer Drugs. 2018 Apr;29(4):373-379. doi: 10.1097/CAD.0000000000000603.

2.

Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).

Issa OM, Roberts R, Mark DB, Boineau R, Goertz C, Rosenberg Y, Lewis EF, Guarneri E, Drisko J, Magaziner A, Lee KL, Lamas GA.

Am Heart J. 2018 Jan;195:70-77. doi: 10.1016/j.ahj.2017.09.002. Epub 2017 Sep 8.

3.

High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.

Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, Violet PC, Pessetto Z, Godwin AK, Fan F, Levine M, Drisko JA, Chen Q.

Sci Rep. 2017 Dec 7;7(1):17188. doi: 10.1038/s41598-017-17568-8.

4.

Active Collaboration with Clients: An Underemphasized but Vital Part of Evidence-Based Practice.

Drisko J.

Soc Work. 2017 Apr 1;62(2):114-121. doi: 10.1093/sw/swx003.

PMID:
28339592
5.

Topological frustration of artificial spin ice.

Drisko J, Marsh T, Cumings J.

Nat Commun. 2017 Jan 13;8:14009. doi: 10.1038/ncomms14009.

6.

Nutritional and Metabolic Biomarkers in Autism Spectrum Disorders: An Exploratory Study.

Esparham AE, Smith T, Belmont JM, Haden M, Wagner LE, Evans RG, Drisko JA.

Integr Med (Encinitas). 2015 Apr;14(2):40-53.

7.

The Next Generation of Dietitians: Implementing Dietetics Education and Practice in Integrative Medicine.

Wagner LE, Evans RG, Noland D, Barkley R, Sullivan DK, Drisko J.

J Am Coll Nutr. 2015;34(5):430-5. doi: 10.1080/07315724.2014.979514. Epub 2015 May 11. Review.

PMID:
25961884
8.

Role of yoga as an adjunctive therapy in patients with neurocardiogenic syncope: a pilot study.

Gunda S, Kanmanthareddy A, Atkins D, Bommana S, Pimentel R, Drisko J, Dibiase L, Beheiry S, Hao S, Natale A, Lakkireddy D.

J Interv Card Electrophysiol. 2015 Aug;43(2):105-10. doi: 10.1007/s10840-015-9996-1. Epub 2015 Apr 12.

PMID:
25863799
9.

Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.

Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz C, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA; TACT Investigators.

Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):508-16.

10.

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL.

Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.

11.

High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.

Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q.

Sci Transl Med. 2014 Feb 5;6(222):222ra18. doi: 10.1126/scitranslmed.3007154.

12.

Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT (Trial to Assess Chelation Therapy) Investigators.

Ann Intern Med. 2013 Dec 17;159(12):797-805.

13.

Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer.

Yu J, Ma Y, Drisko J, Chen Q.

Curr Ther Res Clin Exp. 2013 Dec;75:8-14. doi: 10.1016/j.curtheres.2013.04.001.

14.

Pediatric Integrative Medicine Approaches to Attention Deficit Hyperactivity Disorder (ADHD).

Esparham A, Evans RG, Wagner LE, Drisko JA.

Children (Basel). 2014 Aug 27;1(2):186-207. doi: 10.3390/children1020186. Review.

15.

A convenient method for measuring blood ascorbate concentrations in patients receiving high-dose intravenous ascorbate.

Ma Y, Sullivan GG, Schrick E, Choi IY, He Z, Lierman J, Lee P, Drisko JA, Chen Q.

J Am Coll Nutr. 2013;32(3):187-93. doi: 10.1080/07315724.2013.791167.

16.

Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.

Yu J, Drisko J, Chen Q.

Oncol Rep. 2013 Jul;30(1):149-56. doi: 10.3892/or.2013.2461. Epub 2013 May 14.

PMID:
23674070
17.

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators.

JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.

18.

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.

Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ.

Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.

19.

Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study.

Lakkireddy D, Atkins D, Pillarisetti J, Ryschon K, Bommana S, Drisko J, Vanga S, Dawn B.

J Am Coll Cardiol. 2013 Mar 19;61(11):1177-82. doi: 10.1016/j.jacc.2012.11.060. Epub 2013 Jan 30.

20.

Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy.

Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q.

Anticancer Drugs. 2012 Apr;23(4):437-44. doi: 10.1097/CAD.0b013e32834fd01f.

PMID:
22205155
21.

Design of the Trial to Assess Chelation Therapy (TACT).

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL.

Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.

22.

Reducing cardiovascular disease risk using patient navigators, Denver, Colorado, 2007-2009.

Shlay JC, Barber B, Mickiewicz T, Maravi M, Drisko J, Estacio R, Gutierrez G, Urbina C.

Prev Chronic Dis. 2011 Nov;8(6):A143. Epub 2011 Oct 17.

23.

Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies.

Dusing RW, Drisko JA, Grado GG, Levine M, Holzbeierlein JM, Van Veldhuizen P.

Urol Clin North Am. 2011 Aug;38(3):343-57. doi: 10.1016/j.ucl.2011.04.003.

PMID:
21798397
24.

Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models.

Chen P, Stone J, Sullivan G, Drisko JA, Chen Q.

Free Radic Biol Med. 2011 Aug 1;51(3):681-7. doi: 10.1016/j.freeradbiomed.2011.05.031. Epub 2011 May 30.

PMID:
21672627
25.

Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.

Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q.

Free Radic Biol Med. 2011 Jun 1;50(11):1610-9. doi: 10.1016/j.freeradbiomed.2011.03.007. Epub 2011 Mar 12.

26.

Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.

Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M.

PLoS One. 2010 Jul 7;5(7):e11414. doi: 10.1371/journal.pone.0011414.

27.

New options for child health surveillance by state health departments.

Rosenberg KD, Hembroff L, Drisko J, Viner-Brown S, Decker K, Lichter E.

Matern Child Health J. 2011 Apr;15(3):302-9. doi: 10.1007/s10995-010-0589-4.

PMID:
20232127
28.

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice.

Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9. doi: 10.1073/pnas.0804226105. Epub 2008 Aug 4.

29.

Parent opinions about the appropriate ages at which adult supervision is unnecessary for bathing, street crossing, and bicycling.

Porter TR, Crane LA, Dickinson LM, Gannon J, Drisko J, DiGuiseppi C.

Arch Pediatr Adolesc Med. 2007 Jul;161(7):656-62.

PMID:
17606828
30.

Frontline worker perceptions of the empowerment process in community-based agencies.

Everett JE, Homstead K, Drisko J.

Soc Work. 2007 Apr;52(2):161-70.

PMID:
17580777
31.

Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics.

Drisko J, Bischoff B, Hall M, McCallum R.

J Am Coll Nutr. 2006 Dec;25(6):514-22.

PMID:
17229899
32.

Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis.

Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R.

Dig Dis Sci. 2005 Jun;50(6):1113-7.

PMID:
15986864
33.

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group.

J Urol. 2004 Mar;171(3):1194-8.

PMID:
14767299
34.

Probiotics in health maintenance and disease prevention.

Drisko JA, Giles CK, Bischoff BJ.

Altern Med Rev. 2003 May;8(2):143-55. Review.

35.

The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.

Drisko JA, Chapman J, Hunter VJ.

J Am Coll Nutr. 2003 Apr;22(2):118-23.

PMID:
12672707
36.

The use of antioxidant therapies during chemotherapy.

Drisko JA, Chapman J, Hunter VJ.

Gynecol Oncol. 2003 Mar;88(3):434-9. Review.

PMID:
12648599
37.

A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.

Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, Pearson J, Krupa D, Bach M, Drisko J; Rofecoxib Prostatitis Investigator Team.

J Urol. 2003 Apr;169(4):1401-5.

PMID:
12629372
38.

Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula.

Martin WJ, McGowan E, Cashen DE, Gantert LT, Drisko JE, Hom GJ, Nargund R, Sebhat I, Howard AD, Van der Ploeg LH, MacIntyre DE.

Eur J Pharmacol. 2002 Nov 1;454(1):71-9.

PMID:
12409007
39.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, McGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LH, Patchett AA, Nargund RP.

J Med Chem. 2002 Oct 10;45(21):4589-93.

PMID:
12361385
40.

A role for the melanocortin 4 receptor in sexual function.

Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11381-6. Epub 2002 Aug 9.

41.
42.

A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.

DeVita RJ, Walsh TF, Young JR, Jiang J, Ujjainwalla F, Toupence RB, Parikh M, Huang SX, Fair JA, Goulet MT, Wyvratt MJ, Lo JL, Ren N, Yudkovitz JB, Yang YT, Cheng K, Cui J, Mount G, Rohrer SP, Schaeffer JM, Rhodes L, Drisko JE, McGowan E, MacIntyre DE, Vincent S, Carlin JR, Cameron J, Smith RG.

J Med Chem. 2001 Mar 15;44(6):917-22.

PMID:
11300873
43.

"Natural" isomolecular hormone replacement: an evidence-based medicine approach.

Drisko JA.

Int J Pharm Compd. 2000 Nov-Dec;4(6):414-20. No abstract available.

PMID:
23981731
44.

Low birth weight: a women's health issue.

Johnson T, Drisko J, Gallagher K, Barela C.

Womens Health Issues. 1999 Sep-Oct;9(5):223-30. No abstract available.

PMID:
10560320
45.

Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig.

Drisko JE, Faidley TD, Zhang D, McDonald TJ, Nicolich S, Hora DF, Cunningham P, Li C, Rickes E, McNamara L, Chang C, Smith RG, Hickey GJ.

Proc Soc Exp Biol Med. 1999 Oct;222(1):70-7.

PMID:
10510248
46.

Multi-method assessment of access to primary medical care in rural Colorado.

Fryer GE Jr, Drisko J, Krugman RD, Vojir CP, Prochazka A, Miyoshi TJ, Miller ME.

J Rural Health. 1999 Winter;15(1):113-21.

PMID:
10437338
47.

Hypophyseal-portal concentrations of growth hormone-releasing factor and somatostatin in conscious pigs: relationship to production of spontaneous growth hormone pulses.

Drisko JE, Faidley TD, Chang CH, Zhang D, Nicolich S, Hora DF Jr, McNamara L, Rickes E, Abribat T, Smith RG, Hickey GJ.

Proc Soc Exp Biol Med. 1998 Feb;217(2):188-96.

PMID:
9452143
48.

Transorbital approach to the porcine pituitary.

Drisko JE, Faidley TD, Hora DF Jr, Niebauer GW, Feeney WP, Friscino BH, Hickey GJ.

J Invest Surg. 1996 Jul-Aug;9(4):305-11.

PMID:
8887068
49.

Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585.

Hickey GJ, Drisko J, Faidley T, Chang C, Anderson LL, Nicolich S, McGuire L, Rickes E, Krupa D, Feeney W, Friscino B, Cunningham P, Frazier E, Chen H, Laroque P, Smith RG.

J Endocrinol. 1996 Feb;148(2):371-80.

PMID:
8699151
50.

Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland.

Smith RG, Pong SS, Hickey G, Jacks T, Cheng K, Leonard R, Cohen CJ, Arena JP, Chang CH, Drisko J, Wyvratt M, Fisher M, Nargund R, Patchett A.

Recent Prog Horm Res. 1996;51:261-85; discussion 285-6. Review.

PMID:
8701083

Supplemental Content

Loading ...
Support Center